The etiology of infl ammatory bowel disease (IBD) has not yet been clarifi ed and immunosuppressive agents which nonspecifi cally reduce infl ammation and immunity have been used in the conventional therapies for IBD. Evidence indicates that a dysregulation of mucosal immunity in the gut of IBD causes an overproduction of infl ammatory cytokines and traffi cking of effector leukocytes into the bowel, thus leading to an uncontrolled intestinal infl ammation. Under normal situations, the intestinal mucosa is in a state of "controlled" infl ammation regulated by a delicate balance of proinfl ammatory (tumor necrosis factor [TNF-α], interferon-gamma [IFN-γ], interleukin-1 [IL-1], IL-6, IL-12 and anti-infl ammatory cytokines IL-4, IL-10, IL-11). The mucosal immune system is the central effector of intestinal infl ammation and injury, with cytokines playing a central role in modulating infl ammation. Cytokines may therefore be a logical target for infl ammatory bowel disease therapy using specifi c cytokine inhibitors. Biotechnology agents targeted against TNF, leukocyte adhesion, Th1 polarization, T cell activation, nuclear factor-kappaB (NF-κB), and other miscellaneous therapies are being evaluated as potential therapies for the treatment of infl ammatory bowel disease. In this context, infl iximab and adalimumab are currently the only biologic agents approved in Europe for the treatment of infl ammatory Crohn's disease. Other anti-TNF biologic agents have emerged, including CDP571, certolizumab pegol, etanercept, onercept. However, ongoing research continues to generate new biologic agents targeted at specifi c pathogenic mechanism involved in the infl ammatory process. Lymphocyte-endothelial interactions mediated by adhesion molecules are important in leukocyte migration and recruitment to sites of infl ammation, and selective blockade of these adhesion molecules is a novel and promising strategy to treat Crohn's disease. Therapeutics agents to inhibit leukocyte traffi cking include natalizumab (approved for use in Crohn's disease in USA), MLN-02, and ISIS 2302. Other agents being investigated for the treatment of Crohn's disease include inhibitors of T cell activation, proinfl ammatory cytokine receptors, Th1 polarization, growth hormone, and growth factors. Agents being investigated for treatment of ulcerative colitis include many of those mentioned above. Controlled clinical trials are currently being conducted, exploring the safety and effi cacy of old and new biologic agents, and the search certainly will open new and exciting perspective on the development of therapies for infl ammatory bowel disease. A review is made of the main areas of research exploring the mechanisms associated with the pathogenesis of IBD, providing advances in the agents currently in use, and identifying a host of new therapeutic biologic targets.
Introduction
Infl ammatory bowel diseases (IBD) are chronically relapsing intestinal infl ammatory conditions with a typical onset in young adulthood and with an unpredictable disease course that may lead to debilitating complications. Crohn's disease (CD) and ulcerative colitis (UC) are two main phenotypes of IBD. 1 Their etiopathogenesis has not been clearly elucidated but is thought to involve a complex interplay among genetic, environmental, microbial and immune factors. Thus, a more integrated approach (including different disciplines such as molecular microbiology, immunophysiology, and psychoneuroimmunology) may provide a more complete understanding of the IBD's pathogenesis.
Lifelong pharmacotherapy has remained the cornerstone of IBD management, whereas surgery has been relegated to treatment of refractory disease or specifi c complications.
Current guidelines about conventional IBD therapy recommend use of. aminosalicylates (sulphasalazine, 5-aminosalicylic acid), corticosteroids, immunosuppressive drugs (azathioprine [AZA], 6-mercaptopurine , methotrexate [MTX] , cyclosporin A [CyA]), the selection of which depends on the clinical goal (induction or remissionmaintenance), extent and severity of disease, response to current or prior treatment, and the presence of complications. 2 Aminosalicylates are considered fi rst-line therapy for mild to moderate UC and CD; although effective in UC, inducing remission in 40% to 80% of patients, with 54% to 88% remaining in long-term remission, 3 their effi cacy is more controversial in CD. [4] [5] [6] The therapeutic effi cacy of 5-ASA may depend on the mucosal concentration. Combining topical and oral therapy can increase mucosal concentration 100-fold, which is more effective in refractory UC. A new delivery system also controls the colonic release of 5-ASA through a multi-matrix (MMX) of hydrophilic polymer and lipophilic excipients enclosed in a coated tablet (SPD-476). This may enhance mucosal delivery to the sigmoid colon.
Corticosteroids are indicated for moderate to severe UC or CD or for patients who do not respond to fi rst-line therapy and provide response rates of 45% to 90% in UC and 60% to 78% in CD. 7 Corticosteroids suppress active infl ammation in the acute setting, but they are ineffective maintenance agents with a side-effect profi le that does not allow long-term treatment and they can have a high relapse rate. Moreover, most patients lose response to steroids over time. In addition, one year after starting corticosteroids, only 48% of UC and 32% of CD patients are corticosteroid-free without surgery, 8 which underscores the importance of maintenance therapy after a steroid-induced remission.
Thiopurines (AZA, 6-MP) are effective maintenance immunosuppressant agents indicated for steroid-dependent patients [9] [10] [11] [12] or after a cyclosporine-induced remission, 13 but are limited by their slow onset of action and potential serious adverse events and toxicity 14 (mostly toxic hepatitis, pancreatitis and lymphopenia, opportunistic infections).
CyA is a more rapidly acting therapeutic option for severe UC and CD 15 refractory to conventional therapy; however, its use is restricted to experienced centers equipped to monitor blood levels because it is associated with signifi cant and potential risks of hypertension, nephrotoxicity, electrolyte imbalance, encephalopathy, tremors, myelosuppression, opportunistic infections, and seizures. 2 The current guidelines advice continuing AZA/6MP therapy during pregnancy because some studies showed no incidence difference in miscarriage, preterm delivery, low birth weight, or fetal malformation.
MTX has been established as an inductive agent for steroid-dependent CD (remission rate 39.4%) and for mainteinance of remission after successful induction (65% relapse-free after 40 weeks). [16] [17] However, MTX can produce potential myelosuppression, hepatotoxicity, and teratogenic and abortigenic effects.
In the last decade the management of refractory IBD has been changed dramatically by the advent of biologic therapies. The novel biologic agents, created with genetic technology and directed against a specifi c infl ammatory mediator, have found some of their fi rst real clinical applications in the treatment of IBD. A better understanding of mucosal immune pathology in Crohn's disease and the insights in the effect of gut mucosal cytokines and their importance in the infl ammatory process have led to the development of new therapies with selective targets in the immune pathway. [18] [19] [20] We review the main areas of research and explore the mechanisms more intimately associated with the development of IBD, identifying a host of new therapeutic agents potentially interacting with or interrupting specifi c targets in the pathogenesis of IBD (Tables 1 and 2) .
Moreover, some guidelines summarizing the recommendations for use of biologics agents in the clinical practice will be provided.
Pathogenetic background Genetic factors
IBD is now thought to represent a chronic disease characterized by a diffuse infl ammation of the intestinal mucosa associated with a dysregulation of the mucosal immune system, and an inappropriate response of the intestinal mucosal immune system to otherwise innocuous luminal antigens in a genetically susceptible host. 21 Although CD and UC are considered to be an adaptive disease driven by the immune system, the quest for IBD-related genes has indicated that in some patients, defi ciencies in the innate immune response can be linked to the development of IBD.
Genetic variations in the genes that play a role in the innate and adaptative immune systems are the result of an everlasting arms race between the human species and its environment.
Biologic targeting in the treatment of IBD
There is ample evidence that IBD are, in part, the result of a genetic predisposition, with multiple susceptibility genes, some common to both diseases and some linked separately to one disease or the other. Recently, a gene conferring susceptibility to CD was identifi ed by genome-wide screening, on chromosome 16 in families with several affected members. 22, 23 The gene, known as NOD2/CARD15, is similar to the R factor genes of plants conferring resistance to infection, and was designed as IBD1 locus. Mutations of the NOD2/CARD15 gene in this region have been conclusively associated with CD. NOD proteins are thought to be cytosolic receptors for pathogenic bacterial signals; NOD2 is expressed in monocytes and activates nuclear factor kappaB (NF-κB), which is a key transcriptional factor involved in the onset of immunoinfl ammatory responses. 24, 25 However, there are controversial results in experimental studies about the relationship between mutated NOD2 and activation of NF-κB (decrease or increase), depending on the experimental settings. Mutations are no more frequent in patients with UC than in controls, supporting the theory that CD and UC are related, but different, disorders. As far as the modes by which the NOD2/CARD15 confers susceptibility to CD are concerned, two hypotheses have been advanced based on the molecular domains of the molecule. One is that the presence of the caspase activation and recognition domains indicates that NOD2/CARD15 plays a role in apoptosis. 26 The other is that the presence of the leucine-rich repeat domain indicates that the NOD2/CARD15 protein has a role in the recognition of microbes and innate immunity, because regions of leucine-rich repeat are a feature of the proteins that identify molecular patterns of microbial products, the so-called pattern-recognition receptors. Thus the NOD proteins may represent another family of pattern-recognition receptors, in that NOD1 and NOD2 bind endotoxins intracellularly, resulting in activation of the transcription factor NF-κB, which, in turn, activates the production on infl ammatory cytokines. NF-κB is increased in the lesions of CD, as are numerous infl ammatory cytokines whose transcription is mediated by NF-κB, including tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), IL-6, and IL-12. Multiple receptors are linked to the NF-κB signal-transduction pathway, such as those for the infl ammatory cytokines IL-1 and TNF-α, which have a major role in CD, the toll-like receptors (TLRs), and NOD2. Thus, NF-κB is a fi nal common pathway for a number of infl ammatory signals, and its inhibition is a rationale target for drug therapy. Moreover, any understanding of the contributions of NOD2/CARD15 mutations to the development of CD would be not useful without a determination of which specifi c features or clusters of features of the disease are referred to as phenotypes.
Recently several more IBD susceptibility gene have been identifi ed. A widely replicated associated locus is the IBD5 locus on chromosome 5q31-q33 encoding for the organic cation transporters 1 and 2: unfortunately, the causative IBD susceptibility gene from this region has not yet been unequivocally identifi ed. A recent genome-wide association scan identifi ed a coding single nucleotide polymorphism (SNP), within the autophagy-related 16-like 1 gene (ATG16L1) on chromosome 2q37.1, to be strongly associated with CD. Finally, a genome-wide association study found that genetic variation in the interleukin 23 receptor gene (IL23R) has a protective effect for developing CD. 27 
Environmental factors
The importance of environmental factors is supported by the striking increase in the frequency of CD in the moredeveloped world over the past 50 years, and the increased recognition of the disease, with progressive industrialization in less developed countries. Elements within a changing environment that might affect development of the mucosal immune system, the enteric microfl ora, or both, include improved hygiene, consumption of sterile and nonfermented foods, vaccination, and age at fi rst exposure to intestinal pathogens. 28 During the last few years, with improvements in the socioeconomic conditions of the developing world, the IBD incidence is increasing. In the attempt to offer an explanation for temporal changes in disease frequency and the high prevalence of genes that predispose individuals to CD, it is suggested that the same genes confer selective advantage, such as mucosal immunoprotection in an unsanitary world. The effects of poor hygiene at early childhood are diverse. In some situations, poor hygiene can lead to increased pathogenic infections, but in others, it results in a higher exposure to harmless microorganisms and priming of the regulatory immune system, thus lowering the risk for development of IBD. With a changing environment and lifestyle in an industrialized society, this advantage ceases and becomes a liability since it is associated with a greater mucosal immune responsiveness as well as the risk of progression from physiological to pathological mucosal infl ammation. The decrease in infections from helminthic parasites in the developed world is one aspect of this environmental hypothesis, and has been mechanistically associated with the rise in prevalence of CD. 29 Helminths are associated with a type-2 helper T cell response (Th2), which would counterbalance the type-1 helper T cell response (Th1) of CD. The effects of poor hygiene are diverse. In some situations, poor hygiene can lead to increased pathogenic infections, but in others, it results in a higher exposure to harmless microorganisms and priming of the regulatory immune system, thus lowering the risk for development of IBD.
Other environmental factors could affect the disease phenotype. The effect of cigarette smoking or the opposite effect of this condition on the outcome of each form of IBD represents the most intriguing connection between environmental factors and IBD. Most reports have shown that no smoking is a feature of patients with UC, whereas smoking is a feature of patients with CD. 30, 31 Cigarette smoking has been shown to affect cellular and humoral immunity, 32, 33 and to increase colonic mucus production; 34 whilst both smoking and nicotine 35 have been shown to reduce colonic motility. Finally, results from in vivo studies have shown that nicotine also has an inhibitory effect on Th2 function, which predominates in UC, but has no effect on Th-1 cells, that are predominant in CD. 36 Increased intestinal permeability may play a role in the pathogenesis of CD. A leaky intestinal barrier intensifi es antigen absorption, which, in turn, leads to an exaggerated immune stimulation, perpetuating the infl ammatory process, 37 refl ected at the systemic level by an excessive number of mature B cells. 19 During infl ammation cytoprotective factors, including transforming growth factor-alpha (TGF-α), TGF-β, epidermal growth factor (EGF), keratinocyte growth factor (KGF), IL-11, and growth hormone, are released into intestinal mucosa to restore the integrity of the epithelial cell barrier and promote epithelial restitution and repair. 38 
Microbial factors
Microbial agents appear to be intimately involved in the pathogenesis of IBD. Although available data do not convincingly incriminate a single, persistent pathogen as a universal cause of IBD, this hypothesis should still be considered in view of the possibility that these disorders may represent a heterogeneous group of diseases with multiple etiologies.
During the last few years Mycobacteria paratuberculosis, and measles virus, as well as Listeria monocytogenes have been implicated. 18, 19, 28 However, despite extensive investigations on these and other organisms over the past four decades, no single specifi c infection has convincingly been shown to be critical to the pathogenesis of IBD.
The possibility that components of the normal intestinal fl ora could trigger, initiate, or somehow contribute to IBD is another unknown factor. Bacteria within the enteric lumen have a complex open ecosystem that is continuous with the external environment, and there are up to ten times more bacteria than there are cells in the human body. Differences in microbial ecology in individuals with UC and CD and normal individuals were not strongly supported by early investigations, but more recently, a signifi cant decrease in the number of anaerobic bacteria and Lactobacillus in patients with active, but not inactive, IBD has been found. 39 Moreover, evidence of a relationship between colonic microfl ora and the pathogenesis of UC comes from studies on genetically engineered animals that develop colitis when exposed to nonpathogenic colonic bacterial microfl ora in an environment free from specifi c pathogens, but not when they are in a sterile germ-free environment.
It is reasonable to consider therapeutic approaches that eliminate the bacterial antigens and adjuvants that constantly drive the pathogenic immune response as a potentially important component in treating IBD, in concert with anti-infl ammatory and immunosuppressants agents. Use of narrow-and broadspectrum antibiotics, probiotics (benefi cial bacteria), prebiotics (dietary components that foster the growth of benefi cial bacteria), or the combination of each of these approaches has considerable logic, but at the moment are supported by few controlled studies.
This complex interplay of genetic, microbial, and environmental factors culminates in a sustained activation of the mucosal immune and nonimmune response, likely facilitated by defects in the intestinal epithelial barrier and mucosal immune system, resulting in active chronic infl ammation and tissue damage.
Immuno-infl ammatory factors CD4
+ cells and T-helper subsets
Under normal conditions, the intestinal mucosa is in a state of "controlled" infl ammation regulated by a delicate balance of proinfl ammatory and anti-infl ammatory cytokines. The Th17 lineage has emerged from discovery of a new family of cytokines (IL-17 family) and identifi cation of new activities for the pleiotropic cytokines, TGF, and IL-6. Th17 cells appear to have evolved as an arm of the adaptative immune system specialized for enhanced host protection against extracellular bacteria and some fungi or microbes probably not well covered by Th1 or Th2 immunity.
CD is associated with type 1 helper T cell (Th1) cytokines, 19, 41 while UC cytokine patterns are less clear; UC does not fi t clearly into the Th1/Th2 dichotomy but more closely resembles, at least in established disease, a modifi ed Th2 response.
40,41
Thus CD4 + T cells clearly play an important role in shaping the immune response, and the inhibition of Th1 responses could represent a signifi cant goal in the treatment of IBD, especially of CD where the evidence of the Th1 effects is strongest. Moreover, the main abnormality responsible for leading to infl ammation is now known to be an exaggerated T cell response causing mucosal hyper-responsiveness to commensal bacteria. 42 Cross-reactivity of peripheral-blood and coloniclamina-propria CD4 + T cells with indigenous fl ora (bacteroides, bifi dobacteria, and various enterobacteria) in patients with CD and UC suggests that abnormal T cell-specifi c immune responses to host fl ora are important in their pathogenesis. 43 Intestinal Th1 activation and cytokine release is associated with the generation of activated matrix metalloproteinases which are essential mediators of tissue destruction. 44, 45 At least two mechanisms regulate activated mucosal T cells. The fi rst is based on the function of both the effector and regulator T cell subpopulations within the healthy mucosa; effector T cells are capable of causing intestinal infl ammation, and regulatory T cells are able to control or prevent infl ammation. 46 The second mechanism consists of end of immune responses by apoptosis induction in activated T cells once pathogens have been dealt with. In CD patients, mucosal T cells are resistant to apoptosis, which leads to accumulation of T cells and persistence of the infl ammatory response. 47, 48 In UC patients, T cells in the lamina propria are more susceptible to Fas-mediated apoptosis. 49 Furthermore, the Fas ligand (FasL) is strongly expressed by T cells in active UC but not in CD lesions, suggesting that Fas-FasL induced apoptosis plays a part in the mucosal damage of UC. 50 Anti-infl ammatory cytokines IL-10 IL-10 is an antiinfl ammatory cytokine produced by T cells, B cells and monocyte-activated lipopolysaccharides. When the body is presented with an antigen, IL-10 inhibits the production of IL-1α, IL-6, and TNF-α. Thus, it contributes to downregulation of acute infl ammatory responses. In animal models, IL-10 maintains immune homeostasis in the gut and may play a role in the treatment of CD. 51 
IL-11
IL-11 is a novel cytokine derived from mesenchymal cells. It has potent thrombocytopoietic properties and is used as a treatment for thrombocytopenia in cancer chemotherapy. 52 The evaluation of IL-11 for use in CD stems from data showing the positive effects of this cytokine on the mucosal barrier function. IL-11 attenuates the infl ammatory response by inhibiting expression of NF-κB and in turn IL-1, TNF-α, and other proinfl ammatory peptides. 53 Incidental findings of improved intestinal mucosal integrity in models of colitis injury 54 led to studies of IL-11 on animal models of colitis, in which a benefi t was observed. 55, 56 Th1 polarization IL-2 IL-2 is a critical cofactor for the initiation and continuation of a specifi c immune response. IL-2 is produced by native T cells after activation. At the same time, activated T cells elaborate IL-2 receptor, completing an autocrine and paracrine loop-promoting clonal expansion. IL-2 has important effects on other immune cells, including B cells, monocytes, and natural killer (NK) cells. 18, 19, 57 IFN-γ IFN-γ is elevated in all genetic animal models of IBD and seems to be critical in the development of Th1 responses. If the target of IBD therapy is to reduce Th1 responses, then direct neutralization of IFN-γ is a rational approach. Surprisingly, anti-IFN-γ administered to IL-10 knock-out mice showed no benefi t. It is also demonstrated in experimental induced colitis that ablation of IFN-γ gene in T cells does not prevent the disease. infl ammation and a dominant role for IL-23 over IL-12 in central nervous system and joint autoimmune infl ammation has been described. These fi ndings point to IL-23, but not IL-12, as the necessary mediator for organ specifi c autoimmune diseases development. 18, 19, [57] [58] [59] IL-18 IL-18 is a recently described cytokine that mainly exists in activated macrophages and epithelial cells and shares biological activities with IL-12 in driving the development of Th1 by inducing IFN-γ. IL-18 is upregulated in the intestinal mucosal cells of patients with IBD 60 and animal models have shown benefi t of anti-IL-18 antibodies in reducing the severity of colitis. 61 Proinfl ammatory cytokines IL-1 and TNF-α IL-1 and TNF-α share a multitude of proinflammatory properties and appear to be critical to the amplifi cation of mucosal infl ammation in IBD. Both cytokines are primarily secreted by monocytes and macrophages upon activation, and induce intestinal macrophages, neutrophils, fi broblasts, and smooth-muscle cells to elaborate prostaglandins, proteases, and other soluble mediators of infl ammation and injury, as well as other infl ammatory and chemotactic cytokines. An enhanced expression of IL-1 and TNF was found in IBD, and the important role of TNF was also confi rmed in the genesis of these diseases. The effects of TNF in the intestine which may play a role in mucosal infl ammation are disruption of the epithelial barrier, induction of apoptosis of the villous epithelial cells and secretion of chemokines from the intestinal epithelial cells. TNF activates endothelium by upregulating E-selectin and other adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) as well as by inducing the expression of cytokines and chemokines. TNF also activates neutrophils and macrophages and stimulates B cells. It increases the production of IFN-γ by mucosal T cells independently of IL-12 and IL-18.
It activates CD44 in T cells and enhances intraepithelial lymphocyte proliferation and migration. TNF also stimulates stromal cells from the fetal gut to produce matrix metalloproteinases (MMPs), which could lead to tissue injury, mobilizes dendritic cells from the intestine and appears to be a determinant in granuloma formation, 66 and in association with IL-6, IL-1 may contribute to the constitutional symptoms of IBD and lead to the generation of acute phase proteins. 62 TNF-α is translated as a precursor protein which contains an unusually long signal peptide that anchors the protein to the outer membrane. During local and systemic infl ammatory reactions, membrane bound TNF-α is cleaved extracellularly by a specifi c zinc-dependent metalloprotease that has been designated TNF-α converting enzyme (TACE), yielding the soluble homotrimeric form of TNF-α that can act either as a compartmentalized or circulating cytokine.
It was initially thought that cleavage of TNF-α constituted a major fi nal road block for TNF-α production but subsequently it was recognized that membrane expressed TNF-α is biologically active as a homotrimer during cell-cell contact by interacting with both p55 and p75 TNF receptors. 67, 68 TACE is member of the ADAM (a disintegrin and metalloproteinase) family of cell surface proteases, which are induced during infl ammation. 69, 70 Potential sites for therapeutic manipulation along TNF production, processing, and secretion pathway are shown in Figure 1 .
IL-6
IL-6 is a pleiotropic cytokine with a central role in immune regulation, infl ammation, and hematopoiesis. 71 Increased serum concentrations of IL-6 and soluble IL-6 receptor (IL-6R) have been correlated to clinical activity of CD, and animal models have strongly suggested the therapeutic potential of anti-IL-6R monoclonal antibody in CD. 72, 73 Peroxisome proliferator-activated receptors Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of transcription factors whose activities are regulated by high affi nity binding of small lipophilic ligands such as steroid hormones. 74 A new class of antidiabetic drugs, thiazolidinediones, has been developed that bind to the γ subtype of the PPARs. Colonic epithelial cells express high levels of PPARs proteins, and have the ability to produce infl ammatory cytokines that may contribute to the infl ammatory process in UC. 75 
Adhesion molecules and leukocyte recruitment
Lymphocyte infi ltration into the intestinal tract in IBD is mostly mediated by intectation between α4β7 integrin expressed on lymphocyte and one of its specifi c ligand mucosal vascular addressin CAM-1 (MAdCAM-1), expressed on the endothelial cells of the microvasculature in the infl amed intestinal tract. Integrins form a large family of transmembrane proteins required for cell adhesion, attachment of the cell to the extracellular matrix, or to other cells and anchorage of the cytoskeleton to the plasma membrane. Alfa4 integrins are necessary not just for lymphocyte homing, but also for activation and signaling as well as interaction with extracellular matrix protein. In the pathogenesis of IBD, both T-lymphocyte migration into infl amed mucosa and local activation and proliferation contribute to the perpetuation of infl ammation. Lymphocyte traffi cking into the intestinal mucosa is a multi-step process mediated by three essential steps: rolling, adherence and transendothelial migration. 76, 77 Development of monoclonal antibodies against α4 integrin could permit the targeting of lymphocyte traffi cking into the intestine as a novel therapeutic intervention.
Each of the pathogenic mechanisms elucidated above offers a potential target for novel therapeutic intervention. Figure 2 illustrates the targets of biologic therapy.
Defi nition of biologic therapy
Biologic therapies encompass agents with diverse modes of action. They include: (1) native biologic preparations such as blood products and vaccines containing live, attenuated, or killed micro organisms; (2) recombinant peptides or proteins such as growth hormone, erythropoietin, and soon; (3) antibody-based therapy; (4) nucleic acidbased therapies; and (5) cell and gene therapy. 78 At this time, the biotechnology therapies that are being used in clinical practice or investigated for the treatment of IBD are predominantly proteins, usually delivered intravenously or subcutaneously. The types of therapeutic proteins in use include recombinant human proteins with immunoregulatory effects, monoclonal antibodies (chimeric, humanized, and fully human), and fusions proteins. 79 These small molecules can be screened for a specifi c activity against a specifi c targeted step in the pathogenesis of IBD (initiation, stimulation or perpetuation of mucosal infl ammation).
Compared to the development of most compoundbased drugs, development of biologic agents has been relatively rapid. Biologic agents are often developed by selection of candidate peptides of identifi ed physiologic function. Therefore, the time for preclinical development may be relatively short and potentially expensive.
Manipulation of immunoinfl ammatory factors
Inhibitors of T cell activation CD40 ligand CD40 ligand (CD40L), expressed on T-lymphocytes after their interaction with an APC, is an important costimulatory molecule involved in T cell activation. CD40L binds CD40 (expressed on the APC) to stimulate the expression of yet another costimulatory molecule, B7 (on the APC membrane), which in turns binds to CD28 on the cell surface. 80 Inhibition of the cell activation by targeting these molecules is an attractive concept and a potential therapeutic intervention. A humanized monoclonal antibody to CD40L, IDEC-131, has been developed and a phase II trial initiated for CD. However, owing to concerns of thromboembolism, this trial has been halted. 81 Recently a Italian study group demonstrated that engagement of CD40 in human intestinal fi broblast promoted the release of vascular EGF, IL-8, and hepatocyte growth factor. 82 Thus, the CD40-CD40 ligand pathway appears to be crucially involved in regulating inflammation-driven angiogenesis, target of a potential therapeutic approach.
Anti-CD4 antibodies
Anti-CD4 antibodies have been used in a variety of autoimmune diseases, and have also been tested in CD and UC.
A CD4 depleting antibody (cM-T412) was tested in two open studies. 83, 84 Both CD and UC patients achieved clinical and endoscopic improvement/remission after a period of treatment varying from seven to 11 days.
In another three open trials, [85] [86] [87] CD4 nondepleting antibodies (MAX.16H5 and B-F5) were administered to a total of 16 CD and nine UC patients with active disease. Of the nine UC patients, fi ve achieved remission versus only six of 16 CD patients. Thus, CD4 depleting antibodies seem to be more effective means of therapy than nondepleting antibodies. However, this mode of treatment was mostly associated with a signifi cant decrease in CD4 cells, and because of concerns of CD4 lymphopenia, no further studies have been performed. may induce activated T cell apoptosis and production of IL-10, a potent anti-infl ammatory cytokine. 88 In a phase I dose-escalation study, seven patients with severe steroidrefractory UC received two infusions of visilizumab 15 μg/kg one day apart. Data were available only for fi ve patients, all achieving clinical and endoscopic remission that persisted for several months after treatment. Three of fi ve patients discontinued steroid treatment. Adverse events encountered included transient decrease in T lymphocyte counts and cytokine-release symptoms. There were no infective complications. 89 The phase I dose ranging study in UC patients has been reported, 90 but sadly the phase III study was suspended in 2007 when interim analysis showed no benefi t.
Anti-CD3 antibodies

Anti-infl ammatory cytokines IL-10
A dose-response, placebo-controlled study reported that therapy with recombinant IL-10 (rHuIL-10) at doses of 0.5, 1, 5, 10, or 25 μg/Kg intravenously for seven days was benefi cial in 46 refractory CD patients. 91 However, these encouraging preliminary results were not confi rmed by three large placebo-controlled dose-response trials in patients with mild to moderately active or chronically active CD.
In the fi rst, 92 329 patients with CD refractory to treatment were given subcutaneous human recombinant (rhu) IL-10 1, 4, 8, 20 μg/kg or placebo, for 28 days. No statistically signifi cant difference was found between these treatment groups. However, a tendency toward clinical improvement but not remission was observed in the 8 μg/kg dose group. In the second trial, 93 95 patients with mild to moderately active CD were treated with subcutaneous (rhu) IL-10 1, 5, 10, 20 μg/kg, or placebo for 28 days. At the end of the treatment, clinical remission and endoscopic improvement was achieved in 23.5% of patients receiving 5 μg/kg (rhu) IL-10 vs 0% of patients in the placebo group. In the last study, 373 patients with CD who required prednisone or prednisolone (15-25 mg/daily) to maintain CDAI Ͻ 150 were treated with (rhu) IL-10 4, 8 μg/kg, or placebo once daily subcutaneously for two weeks, then three times each week for 26 weeks. At end of 28 weeks of (rhu) IL-10 treatment, intention-to-treat analysis demonstrated no signifi cant difference in the prednisone withdrawal and clinical remission rates between the different (rhu) IL-10 doses and placebo. 94 Finally, a phase II placebo-controlled dose response trial of (rhu) IL-10 failed to show a benefi cial effect in 94 patients with mild to moderately active UC. 95 Development of systemic administration of (rhu) IL-10 by intravenous or subcutaneous routes for the indications of UC and CD has been discontinued because of a lack of effi cacy in these controlled trials. Recent animal studies have suggested that local administration of IL-10 to the colon via genetically engineered lactococcus bacteria that are orally administered may result in high colonic mucosal concentrations of IL-10 and potentially enhanced effi cacy. 96 It is possible that this approach to IL-10 therapy will be an alternative IL-10 therapeutic approach for UC and CD patients.
IL-11
Results of two clinical trials with recombinant human IL-11 (rhIL-11) in patients with CD have been reported thus far. In a placebo-controlled safety study in 76 patients with active CD, subcutaneously administered rhIL-11 was shown to be safe and well tolerated. 97 In a second placebo-controlled study in 148 patients comparing two doses of subcutaneously administered rhIL-11, it was signifi cantly superior in inducing remission after six weeks when compared to placebo, although the placebo 98 The safety profi le of this regimen appeared to be excellent, with only minor injection site reactions occurring more frequently among treated patients.
The effi cacy of rhIL-11 was compared to prednisolone in patients with mild to moderate active CD (CDAI 220-400). In a double-blind, placebo-controlled trial, 51 patients were treated with rhIL-11 (1 mg/weekly) or prednisolone (starting dose 60 mg/daily), for a 12-week follow-up period. At the end of the study, rhIL-11 and prednisolone induced long-term remission (12 weeks) in comparably sized subsets (22% and 21%, respectively) of patients with mild to moderate CD. 99 
Inhibitors of proinfl ammatory cytokines TNF blockers
Infl iximab Among the various biologic agents, infl iximab has received the most attention, and is a biologic agent approved in the USA and Europe for the treatment of patients with moderate to severe CD unresponsive to conventional therapy or a full and adequate course of corticosteroids and immunosuppressive therapy, and to patients with actively draining fi stulas. Recently it was approved also for the treatment of moderateto-severe UC refractory to conventional therapy.
Infl iximab is a monoclonal chimeric antibody, targeting human TNF-α, composed of a human constant region IgG1k light chain, accounting for approximately 75% of antibody, linked to a mouse variable region (25%). 57 Infl iximab is known to bind soluble bioactive TNF in the intestinal mucosa and thereby neutrolize its effect. Infl iximab also binds to membrane-bound TNF and leads to the in vitro destruction of immune cells by antibody-dependent cellular toxicity. Additionally, it has been shown to induce T cell apoptosis. 64 Antagonism of membrane-bound TNF may be particularly important for the long term clinical effects of infl iximab. Binding of infl iximab to membrane-bound TNF on activated T cells has been shown to promote apoptotic T cell death. 64 Initial open label studies, 100, 101 in which infliximab was effective in rapidly inducing clinical and endoscopic improvement/remission, have been confi rmed in several controlled studies.
In the first randomized, placebo-controlled trial, 108 patients with moderate-to-severe CD which is resistant to conventional therapy, were treated with the single intravenous infusion of either placebo or infl iximab at the dose of 5, 10, or 20 mg/Kg. The rate of clinical response at four weeks were 81% for 5 mg/kg, 50% for 10 mg/Kg and 64% for 20 mg/Kg, all of which were signifi cantly higher than that for the placebo-treated group. A good result also for clinical remission at four weeks (33% infl iximab vs 4% placebo). 102 Patients who maintained their response eight weeks after treatment (73/108 patients initially randomized) were re-randomized at week 12 to placebo or 10 mg/kg infl iximab every eight weeks for four additional infusions. A trend toward signifi cance was observed in the response at week 44 (eight weeks after the last infusion) in the infl iximab-treated patients, compared with those receiving placebo. Quality of life was consistently better and serum C-reactive protein (CRP) levels were consistently lower in patients receiving infl iximab. A signifi cant difference was seen in the rate of remission at week 44 between infl iximab and placebo group (52.9% vs 20%, p = 0.013). These data suggest that repeated dosing with infl iximab may provide useful maintenance therapy, particularly in those patients initially achieving remission. 103 The effectiveness of infl iximab for the maintenance therapy for infl ammatory CD was assessed in a large trial called ACCENT I. 104 In this study 573 patients responders to a single infusion of infl iximab 5 mg/kg were randomly assigned repeat infusions of placebo at weeks 2 and 6 and then every eight weeks thereafter until week 46 (group I), repeat infusions of 5 mg/kg infl iximab at the same time-points (group II), or 5 mg/kg infl iximab at weeks 2 and 6 followed by 10 mg/kg (group III). Three hundred and thirty-fi ve patients (58%) responded to a single infusion of infl iximab within two weeks. At week 30, 23/110 (21%) group I patients were in remission, compared with 44/113 (39%) group II and 50/112 (45%) group III.
Infl iximab safety was consistent with that seen in other trials in CD, and the incidence of serious infections was similar across treatment groups.
In addition, an analysis comparing the scheduled and episodic treatment strategies was conducted based on the ACCENT I data. The effi cacy of the scheduled therapy was better than episodic strategy in terms of CDAI score, clinical remission and response rates, anti-infl iximab antibodies production, improvement in IBDQ score, mucosal healing and CD-related hospitalization and surgery. 105 For an evaluation of the infl iximab maintenance therapy for fi stulizing CD, ACCENT II trial was conducted. One hundred and ninety-six CD patients, with draining perianal and enterocutaneous fi stulas who responded to the induction infl iximab 5 mg/kg therapy (weeks 0, 2, 6), received either placebo or infl iximab at the same dose every eight weeks. The median time to the loss of response, response rate and complete fi stula closure rate at week 54 in the infl iximab maintenance group were signifi cantly greater than those in the placebo group. 106 However, reopening of fi stulae is frequent, suggesting the persistence of deep fi stula tracts despite superfi cial healing. Despite closure, most fi stula tracts are still detectable at anal endosonography (AE), and the persistence of the internal tract is a condition at higher risk of fi stula recurrence. For these reasons, regular AE or magnetic resonance evaluation may have an important role in defi ning patients with perianal fi stulizing CD to be treated (or re-treated) with infl iximab. Moreover, short-term regimen doses with infl iximab and long-term treatment trials are necessary.
Initially, infl iximab did not seem to have much therapeutic effect on UC. Two small pilot trials showed disappointing results for the drug in the treatment of refractory UC. 107, 108 Defi nitive evidence for the role of infl iximab in the treatment of UC has been recently offered by the two large placebo-controlled clinical trials ACT 1 and ACT 2.
In the ACT 1 study, 109 364 patients with active UC despite use of corticosteroids/AZA/6-MP, with endoscopic evidence of moderate or severe UC (endoscopy score Ն 2) and a total Mayo score of 6-12 inclusive, were randomized to receive placebo, infl iximab 5 mg/kg or 10 mg/kg at weeks 0, 2, and 6 then every eight weeks through to week 46. Signifi cantly higher proportion of patients receiving infl iximab 5 mg/kg (64%) and 10 mg/kg (61.5%) had a clinical response at week 8 versus placebo-treated patients (37.2%). At week 30, 52.1% and 50.8% of infl iximab-treated patients, respectively, achieved clinical response versus 29.8% of placebo-treated patients. At week 8, 38.8% and 32.0% of infl iximab 5-and 10 mg/kg-treated patients, respectively, achieved clinical remission versus 14.9% of placebo-treated patients. These differences in remission rates persisted at week 30 (33.9%, 5 mg/kg; 36.9%, 10 mg/kg versus 15.7%, placebo). Mucosal healing was achieved at week 8 in 62% and 59% of patients receiving infl iximab 5 and 10 mg/kg, respectively, versus 33.9% of placebo-treated patients. This difference in mucosal healing was maintained at week 30 (50.4%, 5 mg/kg, 49.2%, 10 mg/kg versus 24.8%). The proportion of patients who were able to discontinue corticosteroids while in clinical remission at week 30 was greater in the combined infl iximab treatment group than in the placebo group (21.7% versus 10.1%).
In the ACT 2 study, 109 364 patients suffering from UC, refractory to at least one standard therapy including 5-ASA, corticosteroids or immunosuppressants, were randomized to receive infl iximab 5 mg/kg, infl iximab 10 mg/kg, or placebo at weeks 0, 2, 6, 14, and 22. Signifi cantly more patients with infl iximab 5 mg/kg (64.5%) and 10 mg/kg (69.2%) achieved clinical response at week 8 versus 29.3% who received placebo. At week 30, 47.1% of patients receiving infl iximab 5 mg/kg and 60% receiving 10 mg/kg were in clinical response versus 26% of patients receiving placebo. Clinical remission was performed at week 8 in 33.9% and 27.5% of infl iximab 5 and 10 mg/kg patients, respectively, compared to 5.7% of placebo-treated patients. Differences in remission rates persisted at week 30 (25.6%, 5 mg/kg; 35.8%, 10 mg/kg; 10.6%, placebo). Mucosal healing was achieved at week 8 in 60.3% and 61.7% of patients receiving infl iximab 5 mg/kg and 10 mg/kg, respectively, compared to 30.9% of placebo-treated patients. Mucosal healing at week 30 was achieved in 46.3% and 56.7% of patients receiving infl iximab 5 mg/kg and 10 mg/kg, respectively, versus 30.1% of placebo-treated patients. The proportion of patients who were able to discontinue corticosteroids while in clinical remission at week 30 was signifi cantly greater in both infliximab groups compared with the placebo group (18.3%, 5 mg/kg; 27.3%, 10 mg/kg; 3.3% placebo).
In both trials, infliximab was well tolerated with a safety profi le similar to that previously reported. Thus, in patients with moderate-to-severe UC, infl iximab induces and maintains clinical response, clinical remission and mucosal healing, and permits the tapering of corticosteroids while maintaining remission.
Some studies and very few data are available for treatment of indeterminate colitis with infl iximab. 110, 111 They suggested that patients with indeterminate colitis are more refractory to infl iximab.
Many case reports and small series have been published on the use of infl iximab for treating extraintestinal manifestations of IBD. Thus, infl iximab has been reported to be effective in the treatment of pyoderma gangrenosum, 112 uveitis and spondyloarthropathy associated with IBD. 113, 114 Recent data suggest that initial treatment of the disease with the combination of AZA and infl iximab, a so called "top-down" approach, may be much more effective than the traditional step-up approach using the infl iximab only in therapy-refractory CD. 115 This study included 100 CD patients with a CDAI greater than 220 who were never treated with steroids, immunomodulators, or infl iximab. Patients were randomized to receive treatment with either three infl iximab infusions (weeks 0, 2, 6) and AZA, topical budesonide (9 mg/day), or systemic prednisone (40 mg/day), to be repeated as clinically necessary. In the top-down group, relapsing patients were given repeated infl iximab and steroids when they failed to respond to infl iximab. In the step-up group, infl iximab was given only after failure of immunosuppression. For the top-down approach, a signifi cantly higher remission rate at six months (74.5%) was noted when compared with the step-up group (48.1%). Top-down patients also did signifi cantly better on endoscopic mucosal healing, steroid usage and development of fi stulas. The success of the top-down approach cannot be accounted for by infl iximab solely, as AZA was administered from the start as a maintenance treatment as well.
Although infl iximab is well tolerated in the majority of patients, serious side effects may rarely occur, including serious infections (see below), drug-induced lupus acute infusion reactions, delayed hypersensitivity reactions, demyeliniation, possibly an increased risk of lymphoma, cardiac failure, and death. 116, 117 In clinical trials, infections requiring treatment occurred in 32% of infl iximab-treated patients versus 22% of placebo-treated patients. There was no signifi cant increase in serious infections or sepsis, but pneumonia, sepsis, miliary tuberculosis, and disseminated coccidiomycosis were all observed. In post-marketing surveillance, tuberculosis, histoplasmosis, listeriosis, aspergillosis, and pneumocystis pneumonia have all been observed, leading to death in some instances. As far as tuberculosis is concerned, reactivation of latent tuberculosis is a severe complication with all anti-TNF strategies. By February 2003, active tuberculosis was reported in 350 of more than 400,000 patients treated with infl iximab or a cumulative incidence of 0.46 per 1000 patient-years. Most cases occurred within the fi rst two months after initiation of therapy. The cumulative mortality amounted to 9%. All patients who are candidate to a treatment with an anti-TNF agent should be evaluated for latent tuberculosis with a tuberculin test and chest X-ray. Treatment of latent tuberculosis should be initiated before therapy with infl iximab.
The presence of murine elements in monoclonal antibodies is associated with a risk of immunogenicity. In a prospective study of 125 infl iximab-treated patients, 61% of patients developed antibodies to infl iximab (ATI, formerly called HACA) after the fi fth infusion. 118, 119 These ATI were clearly associated with infusions reactions and loss of response to the drug. Concomitant immunosuppression with AZA, 6-MP, or MTX was able to prevent the formation of ATI.
It is recommended that infl iximab-treated patients be put on a concomitant immunosuppressive agent to reduce the risk of ATI formation and hence reduce the risk of infusion reactions and prolong the duration of response.
There have been several attempts to explain the lack of response observed in about 30% of patients, varying from studies investigating clinical characteristics, 119, 120 (auto) antibodies, 121, 122 and genetic polymorphisms. 121, 123, 124 In a study on 226 CD patients, the response rate was signifi cantly higher in patients with elevated CRP (Ͼ5 mg/l) than in patients with normal CRP values (Ͻ5 mg/l) before treatment (76% versus 46%), suggesting that response was associated with higher systemic infl ammation. 125 The only replicated predictor of response so far has been the concomitant use of an immunosuppressive.
119,120
CDP571
CDP571 is a humanized IgG4 anti-TNF-α antibody with 95% human and 5% murine protein, that is administered intravenously. and has been studied in active CD. A phase II dosefi nding trial demonstrated the short term benefi t of CDP571 10 mg/kg for inducing a clinical response at two weeks in patients with active CD. 126 A phase III trial of CDP571 10 mg/kg again showed short-term benefi t for inducing clinical response at two weeks in patients with active CD but no signifi cant difference at 28 weeks with maintenance dosing every eight weeks. 127 A post-hoc analysis of a subgroup of patients with CRP concentrations Ն10 mg/l demonstrated signifi cantly increased response rates for CDP571 10 mg/kg at both two weeks and 28 weeks. Two controlled trials failed to demonstrate a steroid sparing benefi t of CDP571 in patients with steroid-dependent CD. 128 From these results, CDP571 was considered to be safe but not as effective as infl iximab and further clinical development of CDP571 for the treatment of CD has been discontinued.
Certolizumab pegol
Certolizumab pegol (CZP) is a humanized TNF-α Fab' monoclonal antibody fragment linked to polyethylene glycol that is administered subcutaneously. The PEGylation increases the plasma half life of CZP to approximately two weeks, but it is unlikely to induce in vivo apoptosis. A large double-bind, placebo-controlled phase III trial, the PRECISE program, is composed by four studies (PRECISE 1, 2, 3, 4) . PRECISE 3 and 4 are ongoing as part of the WELCOME study, designed to examine the effects of CZP in patients failing or intolerant to infl iximab.
In the PRECISE 1, 129 662 patients with moderate to severe CD were stratifi ed according to baseline levels of CRP and were randomly assigned to receive either 400 mg of CZP or placebo subcutaneously at weeks 0, 2, 4, and then every four weeks. Primary end points were the induction of a response at week 6 and a response at both weeks 6 and 26. Among patients with a baseline CRP level of at least 10 mg /l, 37% of patients in the CZP group had a response at week 6, as compared with 26% in the placebo group. At both weeks 6 and 26, the corresponding values were 22% and 12%, respectively. In the overall population, response rates at week 6 were 35% in CZP group and 27% in the placebo group; at both week 6 and 26 the response rates were 23% and 16%, respectively. At weeks 6 and 26, the rates of remission in the two groups did not differ signifi cantly. Serious adverse events were 10% in CZP group, compared to 7% in the placebo group. This study showed that induction and maintenance therapy with CZP was associated with a modest improvement in response rates, compared to placebo, but with no signifi cant improvement in remission rates.
Design of the study was different in the PRECISE 2:
130 as induction therapy, 400 mg of CZP was administered subcutaneously at weeks 0, 2, and 4. Patients with a clinical response (CDAI reduction of at least 100 from baseline) at week 6 were randomly assigned to receive 400 mg of CZP or placebo every four weeks through week 24 with follow up through week 26. At week 6, 64% of patients achieved a clinical response that was maintained through week 26 in 62% of patients with a baseline CRP level of at least 10 mg/l who were receiving CZP (versus 34% of those receiving placebo) and in 63% of patients in intention-to-treat population who were receiving CZP (versus 36% receiving placebo). Among patients with a response at week 6, remission (reduction of CDAI at least 150) at week 26 was achieved in 48% of CZP patients and in 29% of placebo group. Serious adverse events (including one case of pulmonary tuberculosis) occurred in 3% of patients receiving CZP and less than 1% of patients receiving placebo.
In conclusion, the patients with a response to induction therapy with CZP were more likely to have a maintained response and a remission at week 26 with CZP treatment than with placebo.
Actually, CZP is available for clinical use in CD in USA but not in Europe. Results from ongoing studies are eagerly awaited.
RDP58
RDP58 is a novel anti-infl ammatory decapeptide able to block TNF production at a post-transcriptional step, 131 and also inhibits production of IFN-γ, IL-2, and IL-12. RDP58 has been shown to be effective in murine and primate models of colitis. 132, 133 In a phase II study, 134 127 patients with mild-to-moderate active UC were randomized to receive placebo or an oral solution of RDP58 at 100, 200, or 300 mg daily for 28 days. Clinical remission was achieved in 72% of patients in the 300-mg group, 70% in the 200-mg group, 29% in the 100-mg group, and 40% in the placebo group, with response rates of 72%, 77%, 33%, and 44%, respectively. There were no differences in adverse events among any of the treatment groups compared with placebo.
Studies in CD have also begun and results from future trials are awaited.
Etanercept
Etanercept is a genetically engineered fusion protein consisting of two recombinant human TNF p75 receptors linked to an Fc portion of human IgG1 fragment. The subcutaneous injection of etanercept at the dose of 25 mg twice weekly, which is an effective dose for rheumatoid arthritis, is a safe but ineffective dose for the treatment of patients with moderate to severe CD. 135 
Onercept
Onercept is a fully human recombinant soluble TNF p55 receptor administered subcutaneously. A pilot study of onercept in patients with active CD showed benefi t at higher dose. 136 A large, placebo-controlled, dose-fi nding study on 207 patients with active CD showed a safe profi le but onercept was no effective at the doses studied for CD patients. 137 Adalimumab Adalimumab (ADA) is a fully human IgG1 monoclonal antibody to TNF-α that is administered subcutaneously. An uncontrolled pilot study demonstrated that adalimumab was well tolerated in patients with CD who lost response, or developed infusion reactions or delayed-type hypersensitivity reactions to infl iximab. 138 In the CLASSIC 1 139 trial 299 infl iximab-naïve patients with active CD were treated with adalimumab. An induction dose of 160 mg followed by 80 mg at week 2 achieved remission in 36% at week 4 (versus 12% placebo). In the CLASSIC II 140 trial, 276 patients enrolled in CLASSIC I received open-label ADA at week 0 and 2; 55 patients in remission at both weeks 0 and 4 were re-randomized to ADA 40 mg every other week, 40 mg weekly or placebo for 56 weeks. At week 56 79% of patients who received ADA 40 mg every other week and 83% who received 40 mg weekly were in remission, compared with 44% for placebo group.
In the CHARM 141 trial, patients received open-label induction therapy with ADA 80 mg at week 0, followed by 40 mg at week 2. At week 4, patients were stratifi ed by response and randomized to double-bind treatment with placebo, ADA 40 mg every other week or ADA 40 mg weekly through week 56. The percentage of randomized responders in remission was signifi cantly greater in the ADA 40 mg every other week and 40 mg weekly groups vs placebo at week 26 (40%, 47% and 17%, respectively) and week 56 (36%, 41%, and 12%, respectively).
In all studies adalimumab was well tolerated, with a safety profi le consistent with previous experience with the drug. Adalimumab is available for clinical use in patients with CD refractory to conventional therapy. Studies in UC are currently ongoing.
Inhibitors of proinfl ammatory cytokine receptors Anti IL-6R
A humanized monoclonal antibody against IL-6R (MRA) has been developed, and its effi cacy in the treatment of active CD was reported. 142 Thirty-six patients with active CD refractory to conventional therapies were randomized to receive biweekly infusions of MRA or placebo, or an alternate MRA/placebo (every-4th-week MRA) regimen for 12 weeks at 8 mg/Kg. The response and remission rates in the MRA biweekly infusion group were signifi cantly higher than in the placebo group (80% vs 31%; 20% vs 0%, respectively); however, the clinical response of the every-4th-week regimen was only 42%. Infusions were well tolerated and, although promising, these preliminary data will need confi rmation from larger trials.
Inhibitors of Th1 polarization and proliferation
Anti-IL-2 receptor (CD25) antibodies (daclizumab and basiliximab)
Daclizumab is a recombinant humanized IgG1 monoclonal antibody to IL-2 receptor (CD25), which blocks the binding of IL-2 to the IL-2 receptor. An open label pilot study of daclizumab suggested that it was benefi cial for patients with active UC. 143 However, a recent placebo-controlled phase II trial of daclizumab at intravenous doses of 1 mg/kg twice with a four-week interval or 2 mg/kg every second week for a total of four doses in 159 patients with active UC failed to show any effi cacy. 144 A recent open-label, pilot trial evaluated the effi cacy of a chimeric monoclonal anti-CD25 antibody, basiliximab, as a steroid-sensitizing agent in steroid-resistant UC. 145 Fifteen patients received basiliximab intravenously in addition to their standard steroid treatment and 80% achieved remission within six weeks. A large study, placebo controlled is required.
Anti-IL-12
In a multicentric, randomized, placebo-controlled, doubleblind, phase II clinical trial, 146 the safety and effi cacy of a human monoclonal antibody against IL-12 was evaluated in 79 patients with active CD. Patients were randomly assigned to receive seven weekly subcutaneously injections of 1 mg/kg or 3 mg/kg of anti-IL-12 or placebo, with either a four-week interval between the fi rst and second injection (Cohort 1) or no interruption between the two injections (Cohort 2). Safety was the primary end point, and rates of clinical response (defi ned by a reduction in CDAI of at least 100 points) and remission (CDAI score of 150 or less) were secondary endpoints. Seven weeks of uninterrupted treatment with 3 mg/kg of anti-IL-12 resulted in higher response rates than did placebo administration (75% vs 25%). At 18 weeks of follow-up, the difference in response rates was no longer signifi cant (69% vs 25%). Differences in remission rates between the group given 3 mg/kg and the placebo group in the Cohort 2 were not signifi cant at the end of treatment or at the end of follow-up (38% and 0%, respectively, at both times). There were no signifi cant differences in response rates among the groups in Cohort 1. The rates of adverse events among patients receiving anti-IL-12 were similar to those among patients given placebo, except for a higher rate of local reactions at injection sites in the former group.
Anti-IFN-γ (Fontolizumab)
Fontolizumab is a humanized monoclonal antibody to IFN-γ. In a phase I/II dose escalation study, 147 28 patients with moderate-to-severe active CD were randomized to receive a single infusion of HuZAF, a humanized anti-IFN-γ monoclonal antibody, at 0.1 mg/kg, 1 mg/kg, or 4 mg/kg, or placebo. A dose-dependent effect was seen, with the highest response and remission rates achieved in the 4-mg group (86% vs 50% and 71% vs 33%, respectively). HuZAF was well tolerated, with a good safety profi le. The results of a larger, double-blind, placebo-controlled study of fontolizumab in patients with moderate-to-severe CD were reported. 148 In this study 133 patients with CDAI scores between 250 and 450 were randomized to receive placebo or 4 mg/kg or 10 mg/kg fontolizumab. The fi rst 42 patients received a single treatment; the subsequent 91 patients received two infusions (days 0 and 28). Fontolizumab had a benefi cial effect on disease activity in patients who received two infusions of drug. This effect was most prominent in patients with objective evidence of infl ammation as defi ned by an elevated concentration of CRP. Safety and tolerability were good, but more information on long-term data, follow-up and duration of remission are needed to defi ne correctly its safety profi le. Two phase II studies of intravenous natalizumab at doses of 3 mg/kg, 3 mg /kg every four weeks × 2 doses, and 6 mg/kg every 4 weeks × 2 doses showed signifi cant short-term benefi t for natalizumab in patients with active CD. 149, 150 A large phase III study in patients with active CD failed to show a benefi t for natalizumab 300 mg every four weeks × 3 doses, primarily due to an unexpectedly high placebo response rate. 151 A post hoc exploratory analysis of a subgroup of patients with elevated CRP concentrations above the normal range demonstrated a signifi cant effect for natalizumab compared with placebo. 151 Patients who responded to natalizumab in the phase III induction study were re-randomized to maintenance therapy with natalizumab 300 mg or placebo every four weeks up to six months (natalizumab withdrawal study). This maintenance study demonstrated a highly signifi cant maintenance benefi t, with the difference between the treatment groups at six months exceeding 30%. 152 Recently, the ability to taper or discontinue oral corticosteroids in patients treated with natalizumab, was evaluated in a randomized, double-blind, placebo-controlled, multicentric study (ENACT-2). 153 The results of this study demonstrated that natalizumab seems to be associated with steroid-sparing effects in patients with CD as evidenced by the ability of the drug to sustain clinical response and/or remission over time following the withdrawal of concomitant corticosteroids. Natalizumab 3 mg/kg e.v. has also demonstrated some evidence of clinical benefi t at two weeks post-infusion in an uncontrolled study in patients with active UC. 154 Although these promising results, due to the report of two cases of polymyeloleukodystrophy (PML) in two patients receiving concomitant natalizumab and beta interferon. PML, which almost invariably occurs in patients with AIDS or leukemia or in organ-transplant recipients, is a fatal opportunistic infection of the central nervous system caused by reactivation of a clinically latent JC polyomavirus infection. The drug which was recently marketed for multiple sclerosis has been taken off the market but recently is re-marketed in USA also for CD with a lot of safety recommendations.
MLN-02
MLN-02 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody against α 4 β 7 integrin that selectively inhibits leukocyte adhesion in the gastrointestinal mucosa.
Fc receptor recognition and binding has been detected, thus eliminating complement fi xation and cytokine release.
A randomized placebo-controlled trail 155 185 patients with mild to moderately active CD were randomized to receive MLN-02 (0.5 or 2.0 mg/kg) or placebo on days 1 and 29. At 2 months, neither treatment group achieved the primary endpoint, which was a statistically signifi cant difference from placebo in achieving clinical response (decrease of Ͼ70 points in CDAI score). There was a statistically signifi cant difference seen between the 2.0-mg/kg and placebo groups (36.9% vs 20.7%) in achieving the secondary end point of clinical remission (CDAI score Ͻ150), and there was a trend toward dose response. The adverse events (nausea and nasopharyngitis) were more frequent in the MLN-02 treatment groups, but no patients discontinued the treatment.
A phase I/II, double-blind, placebo-controlled, ascendingdose trial examined the safety and pharmacology of MLN-02 in 28 patients with moderately severe UC. 156 Patients received a single dose of 0.15 mg/kg MLN-02 s.c., a single dose of 0.15. 0.5, or 2.0 mg/kg e.v. (groups 1-4), or placebo. A meaningful endoscopic response (defi ned as 2-grade improvement) was observed in 1/5, 0/5, 3/5, and 1/5 patients in groups 1-4, respectively, compared to 2/8 patients in the placebo group. In group 3, 40% of patients (0.5 mg/kg MLN-02) had complete endoscopic remission (defi ned as modifi ed Baron's score of 0) and clinical remission (defi ned as a Mayo Clinic Score of 0). MLN-02 appears to be a generally well-tolerated and effective therapy especially for active UC, but further trials are necessary to confi rm the effi cacy of the drug in IBD.
Alicaforsen (ISIS 2302)
The interaction of lymphocyte-associated α 1 β 2 -integrin, also known as leukocyte function antigen (LFA)-1, and its ligand, intercellular adhesion molecule-1 (ICAM-1), is important for the recruitment of leukocytes to infl ammatory sites. ISIS 2302, a 20-base phosphorothioate antisense oligodeoxynucleotide, is designed to hybridize to a 3' untranslated region of human ICAM-1 messenger ribonucleic acid (mRNA). The heterodimer formed is cleaved by ubiquitous ribonuclease H, resulting in a reduction in ICAM-1 protein expression. 157 Initial positive results were reported in a pilot trial, 158 but two subsequent placebo-controlled trials failed to demonstrate effi cacy. The fi rst involved 75 patients treated with subcutaneous ISIS 2302 0.5 mg/kg for durations of two days, one week, two weeks, four weeks, or placebo, and only 3.3% reached steroid-free remission at week 14. 159 The second randomized 299 patients to receive intravenous ISIS 2302 at 2 mg/kg (three times weekly) for two or four weeks, or placebo. 160 Although steroid-free remission rates were similar to those of the placebo group, pharmacodynamic analysis revealed a signifi cant relationship between drug exposure and response, which suggests that ISIS 2302 might have been effective when if given in adequate doses.
ISIS 2302 in enema formulation showed signifi cant improvement in 40 patients with distal UC in a randomized, placebo-controlled trial. 161 
Growth hormone and growth factors
Human growth hormone and a variety of growth factors such as TGF-β, which is secreted by Th3 cells and provides negative feedback on the differentiation of naïve T helper cells to Th1 or Th2 subtypes, epidermal growth factor (EGF), and keratinocyte growth factor-1 (KGF-1), may play an important role in IBD, 162 for their potential use to heal and restore mucosal integrity.
Human growth hormone
Human growth hormone is a regulatory peptide that increases aminoacid and electrolyte uptake by the intestine, decreases intestinal permeability, and induces the expression of insulinlike growth factor I, which in turn stimulates collagen synthesis. The rationale for the use of growth hormone in CD is to reverse the catabolic process associated with infl ammation. In the only placebo-controlled trial, 163 a signifi cant decrease in the CDAI score among 37 patients with moderate-to-severe CD who received subcutaneous growth hormone for four months, compared with placebo (143 ± 144 vs 19 ± 63), was demonstrated. However, the proportion of patients entering remission was not reported. Further controlled trials using the more conventional endpoints of improvement and remission are required.
Epidermal growth factor
Epidermal growth factor is a potent mitogenic peptide produced by salivary and duodenal Brunner's glands which stimulates cell proliferation in the gastrointestinal tract. A phase II study of recombinant epidermal growth factor enemas demonstrated effi cacy in patients with active distal UC. 164 Further trials are needed to confi rm these impressive results. Moreover and most importantly, of concern is the potential for malignant transformation with EGF therapy in UC patients, because it upregulates the expression of protoncogens in patients with known cancer risk.
Sargramostim and fi lgrastim
Sargramostim (recombinant human granulocyte-macrophage colony stimulating factor) and filgrastim (recombinant human granulocyte colony stimulating factor) are hematopoietic growth factors that stimulate cells of the innate immune system, including neutrophils, macrophages, and dendritic cells. They have been shown to be effective in the treatment of genetic syndromes resulting in neutrophil dysfunction such as glycogen storage diseases, Chediak-Higashi syndrome, and chronic granulomatous disease similar to CD. 165, 166 Based on these observations, phase II trials were performed in patients with CD, and suggested that sargramostim and fi lgrastim may be of benefi t in patients with active and fi stulizing CD, possibly via an immunostimulant effect on neutrophils. 167, 168 In a randomized, double-blind, placebocontrolled trial, 169 124 patients with moderately-to-severely active CD (CDAI Ն220 and Յ475 points) were treated with 6 μg/kg/day sargramostim or placebo subcutaneously for 56 days.
At end of this treatment period, signifi cantly more sargramostim than placebo patients showed a Ն100-point response (48% vs 26%) and clinical remission (40% vs 19%).
Conclusions: The state of art biologic agents in IBD
Biologic agents are facing expanding indications in IBD and will undoubtedly benefi t patients in the long-term. Infl iximab has a clear high effi cacy when administered early in the disease course, but more data are needed before it is positioned as a fi rst-line therapy. Infl iximab still needs to be administred intravenously and provides neither cure nor a durable effect after discontinuation.
The novel anti-TNF antibodies adalimumab and certolizumab pegol offer the perspective of subcutaneous out-of-hospital treatment. However both agents still have to stand up to the real world test of long-term therapy in a large patient population. The risk-benefi t ratio for a powerful drug such as infl iximab carries a limited risk of increased infections and possibly of lymphoma, particularly in combination with steroids and/or azathioprine.
With increasing knowledge about the pathogenesis of IBD and the mechanism driving the uncontrolled infl ammation, new agents have entered the arena. The selective adhesion molecule inhibitor, natalizumab, is now approved for CD in the USA, but development has been temporarily discontinued due to unexpected JC virus brain infections. With anti-IL-12 and anti-IFN-γ we are moving closer to the epicenter of immune reaction. This may result in higher effi cacy, but also may raise new safety issues that should be monitored closely.
With recombinant GM-CSF, sargramostim, first attempts at boosting the innate immune system are being made. Therefore, it is likely to be only a pioneering agent that may provide the proof of concept only to be succeeded by more selective agents targeted at the immune innate system. Only agents restoring T cell tolerance long term or repairing the basic dysfunction in the innate immune system may provide the perspective of cure in chronically remitting and fl aring diseases such as IBD. In conclusion, unmet needs for medical treatment include: primary nonresponse to infl iximab, secondary loss of response to infl iximab in CD and UC and long-term fi stula healing in CD. Novel biologic treatments will probably be able to meet most of these needs, but combination therapy and tailoring of the management to the profi le of the patient will most likely be necessary.
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